The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Open accessAbstract
Biliary tract cancer (BTC) represents the second most frequently diagnosed primary liver cancer worldwide following hepatocellular carcinoma, and the overall survival of patients with unresectable disease remains poor. In recent years, the advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic landscape of several malignancies with these agents, which have also been explored in advanced BTC, as monotherapy or in combination with other anticancer agents. However, clinical trials evaluating ICIs in BTC have shown conflicting results, and the clinical benefit provided by immunotherapy seems limited to a small subgroup of BTC patients. Thus, the identification of reliable predictors of the response to immunotherapy represents a significant challenge in this setting. This review provides an overview of the available evidence on the biomarkers predictive of the response to ICIs in patients with advanced BTC, especially focusing on programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), microsatellite instability (MSI), and other emerging biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Genomic spectra of biliary tract cancer
Nakamura, H., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,284
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Abou-Alfa, G. K., Macarulla, T., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V., Borad, M. J., Bridgewater, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,116
Microsatellite Instability as a Biomarker for PD-1 Blockade
Dudley, J. C., Lin, M.-T., Le, D. T., & Eshleman, J. R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1678 · Cited by 931
Tumor microenvironment: Sanctuary of the devil
Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 779
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Piha‐Paul, S. A., Oh, D., Ueno, M., Malka, D., Chung, H. C., Nagrial, A., Kelley, R. K., Ros, W., Italiano, A., Nakagawa, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33013 · Cited by 486
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
Kim, R. D., Chung, V., Alese, O. B., El-Rayes, B. F., Li, D., Al-Toubah, T. E., Schell, M. J., Zhou, J.-M., Mahipal, A., Kim, B. H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0930 · Cited by 450
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., Bridgewater, J., & Okusaka, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt540 · Cited by 391
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, A., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 367
Mazzaferro, V., El-Rayes, B. F., Droz dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0334-0 · Cited by 365
Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
Chang, L., Chang, M., Chang, H. M., & Chang, F. (2018) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000575 · Cited by 345
Ueno, M., Ikeda, M., Morizane, C., Kobayashi, S., Ohno, I., Kondo, S., Okano, N., Kimura, K., Asada, S., Namba, Y., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30086-x · Cited by 328
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 314
Classification, Diagnosis, and Management of Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.09.009 · Cited by 312
Liau, J.-Y., Tsai, J.-H., Yuan, R.-H., Chang, C.-N., Lee, H.-J., & Jeng, Y.-M. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.241 · Cited by 265
The Tumor Microenvironment in Cholangiocarcinoma Progression
Fabris, L., Sato, K., Alpini, G., & Strazzabosco, M. (2021) · Hepatology · doi:10.1002/hep.31410 · Cited by 235
Sabbatino, F., Villani, V., Yearley, J. H., Deshpande, V., Cai, L., Konstantinidis, I. T., Moon, C., Nota, S., Wang, Y., Al-Sukaini, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0715 · Cited by 216
Weinberg, B. A., Xiu, J., Lindberg, M. R., Shields, A. F., Hwang, J. J., Poorman, K., Salem, M. E., Pishvaian, M. J., Holcombe, R. F., Marshall, J. L., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.08.18 · Cited by 185
Emerging molecular therapeutic targets for cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.026 · Cited by 181
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Fontugne, J., Augustin, J., Pujals, A., Compagnon, P., Rousseau, B., Luciani, A., Tournigand, C., Cherqui, D., Azoulay, D., Pawlotsky, J.-M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15602 · Cited by 178
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Yap, T. A., Plummer, R., Azad, N. S., & Helleday, T. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238473 · Cited by 177
The Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Ancevski Hunter, K., Socinski, M. A., & Villaruz, L. C. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 173
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Silva, V. W. K., Askan, G., Daniel, T. D., Lowery, M., Klimstra, D. S., Abou-Alfa, G. K., & Shia, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.10.04 · Cited by 169
Yoo, C., Oh, D. Y., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L.-T., Osada, M., Helwig, C., Dussault, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000564 · Cited by 164
Gani, F., Nagarajan, N., Kim, Y., Zhu, Q., Luan, L., Bhaijee, F., Anders, R. A., & Pawlik, T. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5101-y · Cited by 158
Recent advances of immunotherapy for biliary tract cancer
Rizzo, A., Ricci, A. D., & Brandi, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1853527 · Cited by 138
Self-citationGolan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 134
Immunobiology of cholangiocarcinoma
Loeuillard, E. J., Conboy, C. B., Gores, G. J., & Ilyas, S. I. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.003 · Cited by 131
Ye, Y., Zhou, L., Xie, X., Jiang, G., Xie, H., & Zheng, S. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21376 · Cited by 124
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 120
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
McNamara, M. G., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & Amir, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102084 · Cited by 120
Ioka, T., Ueno, M., Oh, D., Fujiwara, Y., Chen, J., Doki, Y., Mizuno, N., Park, K., Asagi, A., Hayama, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.4_suppl.387 · Cited by 118
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Rizzo, A., Ricci, A. D., Tavolari, S., & Brandi, G. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20203 · Cited by 109
Self-citationSecond-line therapies in advanced biliary tract cancers
Tella, S. H., Kommalapati, A., Borad, M. J., & Mahipal, A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30733-8 · Cited by 108
Rizzo, A., Ricci, A. D., & Brandi, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1837774 · Cited by 101
Self-citationMa, B., Meng, H., Tian, Y., Wang, Y., Song, T., Zhang, T., Wu, Q., Cui, Y., Li, H., Zhang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06804-6 · Cited by 99
Molecular profile of BRCA-mutated biliary tract cancers
Spizzo, G., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A. F., Shields, A. F., Arora, S. P., Khushman, M. M., Salem, M. E., Battaglin, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000682 · Cited by 99
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Powles, T. B., Walker, J., Williams, J. A., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101925 · Cited by 97
Brandi, G., Rizzo, A., Dall’Olio, F. G., Felicani, C., Ercolani, G., Cescon, M., Frega, G., Tavolari, S., Palloni, A., Lorenzo, S. D., et al. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1763484 · Cited by 96
Self-citationEvolution of the Experimental Models of Cholangiocarcinoma
Massa, A., Varamo, C., Vita, F., Tavolari, S., Neia, C. P., Brandi, G., Rizzo, A., Cavalloni, G., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12082308 · Cited by 96
Self-citationImmunotherapy in Biliary Tract Cancer: Worthy of a Second Look
Ricci, A. D., Rizzo, A., & Brandi, G. (2020) · Cancer Control · doi:10.1177/1073274820948047 · Cited by 94
Self-citationIs There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Liang Cheng, C., Antonio Lopez-beltran, B., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 92
Self-citationRizzo, A., & Brandi, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1864325 · Cited by 86
Self-citationBiliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.002 · Cited by 84
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
Ricci, A. D., Rizzo, A., & Brandi, G. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001042 · Cited by 83
Self-citationMertens, J. C., Ilyas, S. I., & Gores, G. J. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.027 · Cited by 82
Ritterhouse, L. L. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22174 · Cited by 81
PD ‐L1 expression in extrahepatic cholangiocarcinoma
Walter, D. H., Herrmann, E. M., Schnitzbauer, A. A., Zeuzem, S., Hansmann, M. L., Peveling‐Oberhag, J., & Hartmann, S. (2017) · Histopathology · doi:10.1111/his.13238 · Cited by 78
Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
Chakrabarti, S., Kamgar, M., & Mahipal, A. (2020) · Cancers · doi:10.3390/cancers12082039 · Cited by 78
Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications
Wu, H., & Chu, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174154 · Cited by 76
Rizzo, A., Mollica, V., Ricci, A. D., Maggio, I., Massucci, M., Llimpe, F. L. R., Fabio, F. D., & Ardizzoni, A. (2019) · Future Oncology · doi:10.2217/fon-2019-0429 · Cited by 76
Self-citationWinkelmann, R., Schneider, M., Hartmann, S., Schnitzbauer, A. A., Zeuzem, S., Peveling‐Oberhag, J., Hansmann, M. L., & Walter, D. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051421 · Cited by 65
New developments in systemic therapy for advanced biliary tract cancer
Morizane, C., Ueno, M., Ikeda, M., Okusaka, T., Ishii, H., & Furuse, J. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy082 · Cited by 62
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer
Abdel‐Wahab, R., Yap, T. A., Madison, R. W., Pant, S., Cooke, M. B., Wang, K., Zhao, H., Bekaii‐Saab, T., Karatas, E., Kwong, L. N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77939-6 · Cited by 53
Zhang, W., Shi, J., Wang, Y., Zhou, H., Zhang, Z., Han, Z., Li, G., Yang, B., Cao, G., Ke, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02745-y · Cited by 42
Immunotherapies in clinical development for biliary tract cancer
Vogel, A., Bathon, M., & Saborowski, A. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868437 · Cited by 31
Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?
Romano, M., Francesco, F. D., Gringeri, E., Giordano, A., Ferraro, G. A., Domenico, M. D., & Cillo, U. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25190 · Cited by 23
Cited by
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
IRnet: Immunotherapy response prediction using pathway knowledge-informed graph neural network
Jiang, Y., Immadi, M. S., Wang, D., Zeng, S., On Chan, Y., Zhou, J., Xu, D., & Joshi, T. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.036 · Cited by 12
Metadata
- Authors
- Rizzo, A., Ricci, A. D., & Brandi, G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-02-01
- Volume
- 13
- Issue
- 3
- Pages
- 558
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3128409629
- Cited by
- 259
- References
- 74
- FWCI
- 45.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.